Coronavirus: Why Africans Should Take Part In Vaccine Trials
There have been numerous scary stories about trials for a coronavirus vaccine being carried out on people in Africa.
However, scientists say that it is vital that Africans take part in these trials, arguing it could jeopardise efforts to find a vaccine that works worldwide – and not just for richer nations.
In March, Tedros Adhanom Ghebreyesus, head of the World Health Organization (WHO), announced a global “solidarity trial” looking at finding promising treatments for Covid-19, the respiratory illness caused by a coronavirus.
As there are no known cures yet, an effective vaccine would play a critical role in preventing and controlling the pandemic, the WHO says.
It would train people’s immune systems to fight the virus stopping them from becoming sick.
So far one vaccine trial has begun in South Africa – and one is one waiting approval in Kenya.
Yet the issue has been plagued by controversy.
And while vocal opposition to vaccinations of any kind is not new, the current debate in Africa centres on a race row.
It was sparked by two French doctors discussing a trial in Europe and Australia looking into whether a tuberculosis vaccine would prove effective against coronavirus.
During the TV debate, they both agreed it should be tested in Africa too, one saying: “If I can be provocative, shouldn’t we be doing this study in Africa, where there are no masks, no treatments, no resuscitation?
The tone of the comments caused a backlash.
“It was a disgrace, appalling, to hear during the 21st Century, to hear from scientists that kind of remark,” said Dr Tedros, who is Ethiopian.
“We condemn this in the strongest terms possible, and we assure you that this will not happen. The hangover from a colonial mentality has to stop.”
Unsurprisingly prominent African personalities added their voice to the outrage, including former footballers Didier Drogba and Samuel Eto’o – both of whom have been victims of racial abuse on and off the pitch during their careers in Europe.
“Do not take African people as human guinea pigs! It’s absolutely disgusting,” Drogba tweeted.
Such anger is well founded as it has been documented that racism and economic discrimination exist in healthcare.
There is evidence that pharmaceutical companies have carried out trials in parts of Africa, with little regard to ethics or even simple respect for human life.
An infamous drug trial was carried out by Pfizer in Nigeria’s northern state of Kano in 1996.
Eleven children died and dozens were left disabled after being given an experimental antibiotic.
It raised serious questions around consent and whether any had been obtained from the parents.
More than two decades on, scientists like Ugandan researcher Catherine Kyobutungi say things have changed and the process is more rigorous and transparent.
“There are safeguards at the individual level,” Dr Kyobutungi, head of the African Population and Research Center (APHRC), told the BBC.
Richard Mihigo, who oversees immunisation and vaccine development for the WHO in Africa, agrees.
“Within the system there are safeguards and also incentives that make it unlikely that Africans will be exposed to unhealthy products.”
Those who conduct the research are not allowed to be involved in the marketing and production of any subsequent drug or vaccine, he explains.
Such assurances are often deafened by a slew of fake news on social media with theories about a plot to carry out harmful vaccinations on black people with the aim of killing them.
For instance, a fake story about the death of seven children in Senegal after they were given a supposed Covid-19 vaccine caused uproar on Facebook.
It began circulating in early April around the same time as the French doctors’ controversial comments – which gave the fake story even more potency.
The WHO has termed the circulation of fake information an “infodemic”, deserving serious attention.
Decades of underfunding
But what has not had serious attention over the years is healthcare systems in Africa.
This is despite a pledge in 2001 by African heads of state to give at least 15% of their annual budget to improving their health sectors.
So far the target has only been reached in five of the continent’s 54 countries – which has repercussions for scientific research.
Africa has a wealth of expertise, but their scientists often go to work elsewhere because of this lack of investment – meaning that research into the African dynamics of health issues are often not addressed.
Those that stay find it difficult to organise partnerships, as sponsors opt for countries with a reliable healthcare infrastructure, meaning most trials are done in Egypt and South Africa.